T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1101
Acadia Pharmaceuticals
ACAD
$5.07B
| $16.4M | ﹤0.01% |
615,169
-485,714
| -44% | -$11.6M |
|
1102
SL Green Realty
SLG
$4B
| $16.4M | ﹤0.01% |
358,000
+285,226
| +392% | +$14.1M |
|
|
LENZ
1103
LENZ Therapeutics
LENZ
$145M
| $16.4M | ﹤0.01% |
1,023,542
+772,411
| +308% | +$22.5M |
|
1104
Healthpeak Properties
DOC
$14.3B
| $16.4M | ﹤0.01% |
1,017,493
+7,222
| +0.7% | +$127K |
|
1105
Element Solutions
ESI
$9.51B
| $16.4M | ﹤0.01% |
654,511
+95,238
| +17% | +$2.47M |
|
1106
Halozyme
HALO
$11.6B
| $16.3M | ﹤0.01% |
242,038
-583,387
| -71% | -$39.2M |
|
1107
RB Global
RBA
$16B
| $16.3M | ﹤0.01% |
157,967
+10,380
| +7% | +$1.05M |
|
1108
Hasbro
HAS
$13.4B
| $16.2M | ﹤0.01% |
198,014
+3,717
| +2% | +$291K |
|
|
BBNX
1109
Beta Bionics
BBNX
$813M
| $16.2M | ﹤0.01% |
532,749
+45,091
| +9% | +$1.2M |
|
1110
Factset
FDS
$10.2B
| $16.1M | ﹤0.01% |
55,632
-654
| -1% | -$184K |
|
1111
McGrath RentCorp
MGRC
$2.94B
| $16.1M | ﹤0.01% |
153,665
-12,936
| -8% | -$1.4M |
|
1112
UDR
UDR
$12B
| $16M | ﹤0.01% |
436,710
+1,706
| +0.4% | +$60.7K |
|
1113
Unum
UNM
$14.5B
| $15.7M | ﹤0.01% |
201,986
+8,768
| +5% | +$671K |
|
1114
Gaming and Leisure Properties
GLPI
$12.5B
| $15.6M | ﹤0.01% |
348,892
-921,154
| -73% | -$40.9M |
|
1115
Zeta Global
ZETA
$7.44B
| $15.5M | ﹤0.01% |
761,555
-2,201,414
| -74% | -$41.1M |
|
1116
Brixmor Property Group
BRX
$9.12B
| $15.5M | ﹤0.01% |
589,857
+56,324
| +11% | +$1.49M |
|
1117
Align Technology
ALGN
$12.4B
| $15.5M | ﹤0.01% |
98,954
-1,182
| -1% | -$169K |
|
1118
Wynn Resorts
WYNN
$10.5B
| $15.5M | ﹤0.01% |
128,398
+2,074
| +2% | +$257K |
|
1119
J.M. Smucker
SJM
$12.7B
| $15.4M | ﹤0.01% |
157,689
+2,067
| +1% | +$214K |
|
1120
Crown Holdings
CCK
$13.1B
| $15.4M | ﹤0.01% |
149,673
+8,242
| +6% | +$803K |
|
1121
CorVel
CRVL
$3.25B
| $15.2M | ﹤0.01% |
224,001
-80,607
| -26% | -$5.84M |
|
1122
Aurora
AUR
$13.4B
| $15.1M | ﹤0.01% |
3,937,588
-1,244,488
| -24% | -$5.7M |
|
1123
Pinnacle West Capital
PNW
$12.2B
| $15.1M | ﹤0.01% |
170,219
-1
| -0% | -$90 |
|
1124
Travere Therapeutics
TVTX
$5.79B
| $15.1M | ﹤0.01% |
394,844
+315,400
| +397% | +$10.3M |
|
1125
Old Republic International
ORI
$10.3B
| $15.1M | ﹤0.01% |
330,507
+18,915
| +6% | +$821K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.